Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 13 of 13 publications.
Skip to main content
Kellier N, Krohn K, Gilsenan AW, Harris DH, Andrews EB, Massica D. Forteo voluntary patient registry: 3-Year progress on a prospective osteosarcoma surveillance study. Poster presented at the American Society for Bone and Mineral Research Annual Meeting; October 6, 2013.
Gilsenan AW, Midkiff KD, Andrews EB, Von Scheele BG, Masica D, Ceberg J. Multinational collaboration: a long-term surveillance program for osteosarcoma and potential exposure to teriparatide. Presented at the 36th meeting of the Scandinavian Sarcoma Group; October 2013.
Midkiff KD, Von Scheele BG, Gilsenan AW, Ceberg J, Alvegård T. Progress update for the postmarketing adult osteosarcoma surveillance study in five Nordic countries. Poster presented at the 36th meeting of the Scandinavian Sarcoma Group; October 2013.
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective study of plasma-derived factor VIII/vWF in immune tolerance induction therapy: the SPIRIT registry. Poster presented at the Annual Meeting of the National Hemophilia Foundation; October 2013.
Harris DH, Midkiff K, Gilsenan A, Kellier N, Masica D, Andrews E. Eight-year results from the US osteosarcoma surveillance study. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. Montreal.
Gilsenan AW, Harris DH, Midkiff KD, Andrews EB, Kellier N, Masica D. Approaches to long-term surveillance for rare cancer events. Poster presented at the 29th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2013. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2013 Aug; 22(Suppl 1):218-9.
Harris DH, Gilsenan AW, Midkiff KD, Harding AA. Navigating the registry-specific approval process for a long-term drug safety surveillance study. Presented at the NAACCR - North American Association of Central Cancer Registries; June 2013.
Midkiff KD, Harris DH, Gilsenan AW, Powell GL. Variations among cancer registries in accessing patients for a drug safety surveillance study. Poster presented at the NAACCR; June 2013.
Gilsenan AW, Andrews EB. Considerations and strategies for benefit-risk assessment in the real-world setting. In: Sashegyi A, Felli J, Noel R, editors. Benefit-risk assessment in pharmaceutical research and development. 1st ed. Boca Raton: United States. CRC Press; 2013. p.153-64.
Gilsenan AW, Harris DH, Midkiff KD, Andrews EB, Massica D. Seeing the big picture in long-term surveillance for rare events. Presented at the North American Association of Central Cancer Registries Annual Conference; 2013.
Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012 Dec;27(12):2429-37. doi: 10.1002/jbmr.1768
Gilsenan AW, Kellier N, Harris DH, Andrews EB, Masica DN. Linking a voluntary patient registry with US state cancer registries for possible signal detection. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug 27; 21(suppl 3):464. doi: 10.1002/pds.3324
Harris DH, Gilsenan AW, Wu Y, Andrews EB. Using cancer surveillance data to advance science: monitoring for a potential safety signal for approved drugs through linkage studies. Poster presented at the Annual Meeting of the North American Association of Central Cancer Registries; 2012.